Biosergen Receives Full Subscription Guarantees for Warrant Exercise from Largest Shareholders and Executive Management

Stockholm, Sweden – August 16 – Biosergen AB ("Biosergen" or the “Company"), a clinical stage biotech company specializing in the development of innovative anti-fungal therapies, is pleased to announce significant guarantees from its largest shareholders and executive management to fully exercise their warrants during the ongoing warrant exercise period.

Östersjöstiftelsen and Rosetta Capital, the Company’s largest shareholders, will exercise all their warrants. In addition CEO Peder M. Andersen and CFO Niels Laursen will subscribe to all of their warrants. Moreover, COO Tine Olesen, who does not currently own any warrants, will also participate in the warrant exercise.

In total, these guaranteed commitments represent more than 48% of the total outstanding TO2 warrants. The guarantors will receive no compensation for their commitment. Therefore, Biosergen can expect to receive a minimum of SEK 2.8 million from the ongoing TO2 warrant exercise from this group of investors.

“We are grateful for the trust and confidence shown by Östersjöstiftelsen and Rosetta Capital. We hope many other investors will join us in this investment opportunity. All management members are committed to creating a successful company. Ultimately, we aim to make a substantial impact in the fight against fungal infections, and we are on a very good track to do so,” commented CEO Peder M. Andersen.